Wu Xiaobin sold $164K of ONC

Wu Xiaobin (President and COO) sold 626 shares of BeOne Medicines Ltd. (ONC) at $261.20 ($0.16M total) on 2026-06-11.

Original reporting
SEC EDGAR · Wu Xiaobin
Published Jun 15, 2026, 9:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ONC
Neutral
high confidence
Mentioned
$ONC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

This adds a fresh, timestamped data point on insider ownership but does not include new clinical, regulatory, financial, or deal information that would typically reprice the stock.

02

Market read

Traders may monitor insider activity as a sentiment input, but the filing alone is unlikely to drive a material repricing without other catalysts.

03

What to watch

The article notes no pre-arranged 10b5-1 plan, which can increase interpretive uncertainty, but the disclosure still lacks any fundamental linkage.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-15 (transaction dated 2026-06-11)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralHigh confidence
Context

SEC Form 4 shows ONC President/COO Wu Xiaobin sold 626 shares in an open-market transaction on 2026-06-11 at $261.2017.

Expected impact

Likely minimal near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

The filing is a Form 4 insider sale with no 10b5-1 plan stated and no accompanying operational/regulatory catalyst in the text.

Market effects

No sector read-across provided; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification/taxes rather than bearish expectations, especially for small share counts.

Key entities

  • BeOne Medicines Ltd.

    Subject of the Form 4 insider transaction disclosure.

  • Wu Xiaobin

    President and COO who sold 626 shares of ONC.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ONCMed

BeOne Medicines Ltd (ONC) Q3 2026 Earnings Call Highlights: Brukinsa Tops $1 Billion

BeOne Medicines reported Q3 2026 earnings, highlighting Brukinsa's U.S. sales exceeding $1 billion. Management discussed competitive threats, R&D investments, and clinical trial updates. Operating margins are expected to expand by over 10% in 2026, with future growth balanced against investment. The company is expanding its CDK4 inhibitor Phase III study and partnering with Revolution Medicines on precision oncology initiatives.

$ONCHighAI 8/10

Jefferies raises BeOne Medicines stock price target on solid quarter

Jefferies raised its price target for BeOne Medicines (ONC) to $470 from $410, citing strong quarterly results and raised guidance. The stock trades near its 52-week high at $387.27. The company reported $1.7B in Q2 2026 revenue, up 29% YoY, and raised its full-year 2026 revenue guidance to $6.6B-$6.8B. Analysts highlight robust margins, revenue growth, and a solid pipeline.

$ONCHighAI 9/10

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year • BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter,

$ONCMed

BeOne Medicines Receives FDA Priority Review for BRUKINSA Combination in First-Line Mantle Cell Lymphoma

BeOne Medicines (ONC) announced FDA Priority Review for BRUKINSA (zanubrutinib) plus rituximab in first-line mantle cell lymphoma, based on Phase 3 MANGROVE trial results showing 43% reduced risk of disease progression or death. If approved, it would be the first chemotherapy-free regimen for this indication. The company is also seeking approvals in Europe and China. BRUKINSA is already approved for other B-cell malignancies.